Search the Newsreel

BioNTech SE Stock 12‑Month Price Target Cut to $121.53, Implies 32% Upside

BioNTech SE's average 12-month price target has been adjusted to $121.53, down from $122.4, according to 19 analysts, with a potential upside of approximately 32% from its Aug. 3 closing price. The consensus rating from 21 analysts remains a "Buy," with 15 Buys and …

BioNTech anticipates €1.6B-€1.9B 2026 revenue while advancing oncology catalysts into late 2026

Earnings Call Insights: BioNTech (BNTX) Q2 2026 MANAGEMENT VIEW * BioNTech framed its leadership transition as tied to commercialization scale, with (Chairman Helmut Jeggle) saying, "Guido Oelkers will take office as CEO as of February 1 at the latest" and highlighting that, at Sobi, …

BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development

BioNTech, a German biotech company founded in 2008, is a leader in personalized mRNA cancer treatments. Having capitalized on its COVID-19 vaccine success, the company has diversified its pipeline through acquisitions, focusing on biologic drug candidates in oncology. These new treatments are expected to …

BioNTech lowers 2026 sales outlook as COVID vaccine demand softens

BioNTech has significantly lowered its 2026 full-year sales outlook due to weaker-than-expected demand for its COVID-19 vaccine, resulting in a more than halved second-quarter revenue and a doubled net loss. The company now projects 2026 revenue between €1.6 billion and €1.9 billion, down from …

BioNTech Q2 Earnings Call Highlights

Key Points Interested in BioNTech SE Sponsored ADR? Here are five stocks we like better. BioNTech's Q2 revenue fell to €106 million from €261 million a year earlier due to weaker U.S. COVID-19 vaccine demand. The company lowered 2026 revenue guidance to €1.6 billion–€1.9 …

BioNTech SE Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

BioNTech SE announced its financial results for the second quarter and six months ended June 30, 2026, reporting a significant decrease in sales and an increase in net loss compared to the previous year. For the second quarter, sales were EUR 105.6 million and …

BioNTech SE (BNTX) Q2 2026 Earnings

BioNTech SE (BNTX) reported its Q2 2026 earnings, missing analyst estimates for both EPS and revenue. The company's EPS was -$2.22 against an estimated -$2.08, and revenue was $106M compared to an estimated $156M. Management also lowered full-year 2026 guidance due to Germany drawing …

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

BioNTech SE Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer, taking office by February 1, 2027, at the latest Advanced diversified pipeline now with 14 ongoing pivotal clinical trials and more than ten novel-novel combinations across major tumor types Multiple …

BioNTech (Nasdaq: BNTX) lowers 2026 revenue view after steep Q2 loss

BioNTech reported a significant Q2 2026 loss of €820.8 million and sharply lower COVID-19 vaccine revenue, leading the company to reduce its full-year 2026 revenue guidance to €1.6–1.9 billion from €2.0–2.3 billion. Despite the financial setbacks, BioNTech is advancing its oncology pipeline with 14 …

Control Bionics Ltd. Revenue Breakdown – ASX:CBL

Control Bionics (ASX:CBL) Advances Global Regulatory Strategy With NeuroStrip FDA Listing

BioNTech says Sobi's Oelkers will replace Sahin as CEO

BioNTech announced that Guido Oelkers, the current CEO of Sobi, will take over as its chief executive from February 1, 2027, at the latest. Oelkers will succeed Ugur Sahin, who along with co-founder Oezlem Tuereci, is set to leave the company by the end …

BioNTech earnings on deck as losses widen amid COVID decline By Investing.com

BioNTech is set to report its second-quarter results with analysts expecting widening losses due to a significant decline in COVID-19 vaccine revenue. Despite the short-term financial headwinds, the company is pivoting towards oncology with promising clinical trial developments in mRNA cancer vaccines. Investors will …

BioNTech Appoints Oelkers As CEO, Succeeding Co-Founder Sahin

(RTTNews) - BioNTech SE (BNTX) announced on Monday that its Supervisory Board has appointed Guido Oelkers to the Management Board as Chief Executive Officer (CEO), effective February 1, 2027, succeeding co-founder and CEO Ugur Sahin. Sahin is a physician and immunologist with experience in …

BioNTech (Nasdaq: BNTX) taps Guido Oelkers to succeed Ugur Sahin as CEO

BioNTech SE has announced the appointment of Guido Oelkers, Ph.D., as its new Chief Executive Officer, succeeding co-founder Prof. Ugur Sahin, M.D. Oelkers, who previously quadrupled revenues at Swedish Orphan Biovitrum AB, is expected to take office by February 1, 2027, and aims to …

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

BioNTech SE has appointed Guido Oelkers, Ph.D., to its Management Board as Chief Executive Officer, effective by February 1, 2027. Oelkers, who previously served as CEO of Swedish Orphan Biovitrum AB, brings over 30 years of experience in the biotechnology and pharmaceutical industries. This …

BioNTech SE (BNTX) Stock Analysis: Navigating a 36% Upside Potential Amidst Revenue Challenges

BioNTech Appoints Guido Oelkers as Chief Executive Officer, Succeeding Ugur Sahin

BioNTech SE has appointed Guido Oelkers, Ph.D., as its new Chief Executive Officer, effective by February 1, 2027, succeeding Prof. Ugur Sahin, M.D. Oelkers brings over 30 years of experience in the biotechnology and pharmaceutical industries and a strong track record of increasing revenue …

Beta Bionics (Nasdaq: BBNX) lifts Q2 sales to $32M amid ongoing losses

Beta Bionics (Nasdaq: BBNX) reported a significant increase in Q2 2026 net sales to $32.0 million, up from $23.2 million a year prior, primarily driven by its iLet insulin delivery device and single-use consumables. Despite this growth, the company continues to experience substantial losses, …

Beta Bionics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BBNX) 2026-07-31

Beta Bionics, Inc. (BBNX) published its Q2 2026 earnings call presentation, reporting an EPS of -$0.36, beating estimates by $0.20, and revenue of $32.01M, surpassing expectations by $533.03K with a 37.76% year-over-year increase. The slide deck was released in conjunction with the company's earnings …

Bionano Genomics, Inc. Revenue Breakdown – NASDAQ:BNGO

Bionano Genomics, Inc. reported a total revenue of $28.51 million USD last year. The largest contributing segment was Consumables, generating $13.97 million USD, an increase from $12.77 million USD in the prior year. Geographically, the EMEA region was the primary revenue driver, contributing $14.11 …

A Quick Look at Today's Ratings for Beta Bionics(BBNX.US), With a Forecast Between $15.5 to $30.4

This article provides an overview of recent analyst ratings for Beta Bionics (BBNX.US), highlighting a forecast range for its stock price between $15.5 and $30.4. It appears to be a summary of current market sentiment regarding the company's valuation.

Diluted shares outstanding of Bionano Genomics, Inc. – GETTEX:2Y3

This article provides financial information for Bionano Genomics, Inc. (GETTEX:2Y3), specifically focusing on its diluted shares outstanding. The content is presented within the TradingView platform, offering various financial data points and tools for analysis.

BioNexus Gene Lab names CFO Chong Set Fui in initial beneficial ownership filing

BioNexus Gene Lab has filed an initial Form 3 for its CFO, Chong Set Fui, dated June 17, 2025. This news brief was generated by Public Technologies using AI and is for informational purposes only, not financial advice. The original content was published via …

Net income before discontinued operations of Bionano Genomics, Inc. – GETTEX:2Y3

This page provides financial data, specifically net income before discontinued operations, for Bionano Genomics, Inc. (2Y3) listed on Gettex. The content is primarily a data placeholder within TradingView's platform, indicating no trades have occurred for this particular metric yet.

BioNexus Gene Lab (BGLC) CEO files Form 3 showing 0.0000 shares

BioNexus Gene Lab Corp (BGLC) CEO and director Tan Lee Su-Leng filed a Form 3, an initial statement of beneficial ownership of securities, reporting 0.0000 shares held directly. This filing, dated August 15, 2023, indicates no buy or sell transactions. The report clarifies that …

BioNexus Gene Lab Corp (BGLC) director reports holding 0 common shares

BioNexus Gene Lab Corp (BGLC) director Bin Abdul Hamid Muhammad Azrul filed a Form 3, an Initial Statement of Beneficial Ownership, reporting direct ownership of 0 shares of common stock as of December 11, 2023. The filing indicates no purchase, sale, or derivative transactions, …

Enterprise value to revenue forward of BioNTech SE – NASDAQ:BNTX

This article provides financial data for BioNTech SE (NASDAQ: BNTX), specifically focusing on its enterprise value to revenue forward. It appears to be a snapshot from a financial data platform, showing the company's ticker, market, and a period value related to this metric, but …

Beta Bionics Earnings Call Highlights Growth And Risks

BioNexus Gene Lab Corp (BGLC) Financial Health: Profitability & Balance Sheet Analysis

BioNexus Gene Lab Corp (BGLC) has a current financial score of 6.04, ranking 292 out of 384 in the Biotechnology & Medical Research industry, indicating a robust financial status despite low operating efficiency. The company's latest quarterly revenue significantly decreased year-over-year by 98.93% to …

BioNexus Gene Lab Corp (BGLC) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for BioNexus Gene Lab Corp (BGLC), assigning it a score of 2.70 out of 384 companies in the Biotechnology & Medical Research industry. Key metrics include a beta value of 2.20, indicating higher volatility compared to the S&P …

Bionano Genomics Inc (BNGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Bionano Genomics Inc (BNGO), detailing its price momentum score of 3.18 and identifying current support at $1.00 and resistance at $1.16. It presents a summary of various technical indicators, such as MACD and RSI, which largely suggest …

Bionano Genomics (BNGO) CSO reports holding 63 shares

Bionano Genomics' Chief Scientific Officer, Alex Reid Hastie, has filed an initial statement of beneficial ownership (Form 3) reporting direct ownership of 63 shares of the company's common stock. This filing indicates no insider purchases or sales in this specific report. It establishes his …

Law firm probes Beta Bionics for possible misleading growth claims affecting investors

Johnson Fistel, PLLP is investigating Beta Bionics for potential securities law violations due to allegedly misleading statements about its growth and new patient starts. This probe was triggered by Beta Bionics' disclosure of significantly slower growth in new patient starts for Q4 2025, which …

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

Johnson Fistel, PLLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) for potential securities law violations after the company disclosed slower new patient start growth for Q4 2025, which fell below analyst expectations and showed significant deceleration from the previous quarter. The law firm is …

Pfizer-BioNTech Secures EU Marketing Authorisation For XFG-Adapted COVID-19 Vaccine

(RTTNews) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced that the European Commission (EC) has granted marketing authorisation for the COVID-19 vaccine formulation targeting the XFG variant, for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and …